IL-7 enhances survival of human CD56bright NK cells

Journal of Immunotherapy

Volumn 33, Issue 4, 2010, Pages 382-390

  Michaud, Annie ^a   Dardari, R'kia ^a   Charrier, Emily ^a   Cordeiro, Paulo ^a   Herblot, Sabine ^a   Duval, Michel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cd127 (il 7r ); Interleukin 7; Natural killer

Indexed keywords

CD56 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR ALPHA; NATURAL KILLER CELL RECEPTOR NKG2A; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CASE REPORT; CELL ISOLATION; CELL MATURATION; CELL POPULATION; CELL SURVIVAL; CHILD; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FEMALE; HOMEOSTASIS; HUMAN; HUMAN CELL; INFANT; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; THYMUS;

EID: 77954951939     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181cd872d     Document Type: Article

References (36)

1. Caligiuri MA. Human natural killer cells. Blood. 2008;112:461-469.
2. Moretta A, Locatelli F, Moretta L. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias. Immunol Rev. 2008;224:58-69.
3. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol. 2002;2:957-964.
4. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.
5. Ruggeri L, Mancusi A, Burchielli E, et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis. 2008;40:84-90.
6. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9:495-502.
7. Gumperz JE, Barber LD, Valiante NM, et al. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cellinhibitory receptor. J Immunol. 1997;158:5237-5241.
8. Litwin V, Gumperz J, Parham P, et al. NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med. 1994;180:537-543.
9. Carretero M, Cantoni C, Bellon T, et al. The CD94 and NKG2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules. Eur J Immunol. 1997;27:563-567.
10. Farag SS, Fehniger TA, Ruggeri L, et al. Natural killer cell receptors: new biology and insights into the graft-versusleukemia effect. Blood. 2002;100:1935-1947.
11. Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med. 2009;266:154-181.
12. Moretta A, Marcenaro E, Parolini S, et al. NK cells at the interface between innate and adaptive immunity. Cell Death Differ. 2008;15:226-233.
13. Freud AG, Becknell B, Roychowdhury S, et al. A human CD34 (+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity. 2005;22:295-304.
14. Chan A, Hong DL, Atzberger A, et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol. 2007;179:89-94.
15. Phillips JH, Hori T, Nagler A, et al. Ontogeny of human natural killer (NK) cells: fetal NK cells mediate cytolytic function and express cytoplasmic CD3 epsilon, delta proteins. J Exp Med. 1992;175:1055-1066.
16. Vosshenrich CA, Garcia-Ojeda ME, Samson-Villeger SI, et al. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol. 2006;7:1217-1224.
17. Puel A, Ziegler SF, Buckley RH, et al. Defective IL7R expression in T (-) B (+) NK (+) severe combined immunodeficiency. Nat Genet. 1998;20:394-397.
18. Sportes C, Gress RE. Interleukin-7 immunotherapy. Adv Exp Med Biol. 2007;601:321-333.
19. Takahashi K, Segal E, Kondo T, et al. Interferon and natural killer cell activity in patients with exanthem subitum. Pediatr Infect Dis J. 1992;11:369-373.
20. Palmer MJ, Mahajan VS, Trajman LC, et al. Interleukin-7 receptor signaling network: an integrated systems perspective. Cell Mol Immunol. 2008;5:79-89.
21. Park JH, Yu Q, Erman B, et al. Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity. 2004;21:289-302.
22. Hanna J, Bechtel P, Zhai Y, et al. Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J Immunol. 2004;173:6547-6563.
23. Zhang Y, Wallace DL, de Lara CM, et al. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology. 2007;121:258-265.
24. Hofmeister R, Khaled AR, Benbernou N, et al. Interleukin-7: physiological roles and mechanisms of action. Cytokine Growth Factor Rev. 1999;10:41-60.
25. Roifman CM, Zhang J, Chitayat D, et al. A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. Blood. 2000;96:2803-2807.
26. Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol. 2005;174:6571-6576.
27. Akashi K, Kondo M, von Freeden-Jeffry U, et al. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell. 1997;89:1033-1041.
28. Armant M, Delespesse G, Sarfati M. IL-2 and IL-7 but not IL-12 protect natural killer cells from death by apoptosis and up-regulate bcl-2 expression. Immunology. 1995;85:331-337.
29. Vitale C, Pitto A, Benvenuto F, et al. Phenotypic and functional analysis of the HLA-class I-specific inhibitory receptors of natural killer cells isolated from peripheral blood of patients undergoing bone marrow transplantation from matched unrelated donors. Hematol J. 2000;1:136-144.
30. Nguyen S, Dhedin N, Vernant JP, et al. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood. 2005;105:4135-4142.
31. Shilling HG, McQueen KL, Cheng NW, et al. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood. 2003;101:3730-3740.
32. Sivori S, Falco M, Marcenaro E, et al. Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc Natl Acad Sci U S A. 2002;99:4526-4531.
33. Bolotin E, Annett G, Parkman R, et al. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant. 1999;23:783-788.
34. Gendelman M, Hecht T, Logan B, et al. Host conditioning is a primary determinant in modulating the effect of IL-7 on murine graft-versus-host disease. J Immunol. 2004;172:3328-3336.
35. Levy Y, Lacabaratz C, Weiss L, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest. 2009;119:997-1007.
36. Sportes C, Hakim FT, Memon SA, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med. 2008;205:1701-1714.